(AOF) – Transgene and NEC presented the first signs of clinical benefit of their individualized cancer vaccine, TG4050, in head and neck cancers at the annual meeting of the American Association for Cancer Research . The 16 patients who received TG4050 are still in remission after a median follow-up of 18.6 months. Of the 16 patients in the observational arm, 3 patients have already relapsed.
For this category of head and neck cancer patients, with current standard treatments, approximately 40% of patients are likely to relapse within 24 months following surgery associated with standard therapy (chemoradiotherapy).
Specific CD4+ and CD8+ immune responses were detected in 16 of 17 patients who received TG4050. Finally, TG4050 induces durable immune responses against multiple targets in several patients. T cell responses were detected 211 days after treatment initiation.
Building on the first results obtained in the Phase I part of the trial, Transgene and NEC are preparing an extension of this trial with a randomized Phase II, scheduled to start in the second quarter of 2024.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
